PH26030A - Use of benzamide in the treatment of cognitive disorders - Google Patents
Use of benzamide in the treatment of cognitive disorders Download PDFInfo
- Publication number
- PH26030A PH26030A PH38119A PH38119A PH26030A PH 26030 A PH26030 A PH 26030A PH 38119 A PH38119 A PH 38119A PH 38119 A PH38119 A PH 38119A PH 26030 A PH26030 A PH 26030A
- Authority
- PH
- Philippines
- Prior art keywords
- treatment
- moclobemide
- dementia
- test
- prevention
- Prior art date
Links
- 208000010877 cognitive disease Diseases 0.000 title claims abstract description 5
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 title claims 4
- 238000000034 method Methods 0.000 claims description 16
- 206010012289 Dementia Diseases 0.000 claims description 11
- 230000002265 prevention Effects 0.000 claims description 7
- 206010061216 Infarction Diseases 0.000 claims description 3
- 230000003412 degenerative effect Effects 0.000 claims description 3
- 230000007574 infarction Effects 0.000 claims 1
- YHXISWVBGDMDLQ-UHFFFAOYSA-N moclobemide Chemical compound C1=CC(Cl)=CC=C1C(=O)NCCN1CCOCC1 YHXISWVBGDMDLQ-UHFFFAOYSA-N 0.000 abstract description 26
- 238000012360 testing method Methods 0.000 description 27
- 239000003826 tablet Substances 0.000 description 26
- 229960004644 moclobemide Drugs 0.000 description 24
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 16
- STECJAGHUSJQJN-VJQRDGCPSA-N chembl3084722 Chemical compound C1([C@@H](CO)C(=O)O[C@@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-VJQRDGCPSA-N 0.000 description 14
- 229960002646 scopolamine Drugs 0.000 description 14
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 13
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 13
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 13
- 239000004615 ingredient Substances 0.000 description 11
- 239000000126 substance Substances 0.000 description 10
- 229920002261 Corn starch Polymers 0.000 description 9
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 9
- 235000019759 Maize starch Nutrition 0.000 description 9
- 239000008101 lactose Substances 0.000 description 9
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 9
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 9
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 235000019359 magnesium stearate Nutrition 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 241000700159 Rattus Species 0.000 description 7
- 239000008367 deionised water Substances 0.000 description 7
- 229910021641 deionized water Inorganic materials 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 6
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 6
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 6
- 239000011248 coating agent Substances 0.000 description 6
- 238000000576 coating method Methods 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 229910052708 sodium Inorganic materials 0.000 description 6
- 239000008107 starch Substances 0.000 description 6
- 239000002775 capsule Substances 0.000 description 5
- 230000006735 deficit Effects 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 229960004499 scopolamine hydrobromide Drugs 0.000 description 5
- WTGQALLALWYDJH-MOUKNHLCSA-N scopolamine hydrobromide (anhydrous) Chemical compound Br.C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 WTGQALLALWYDJH-MOUKNHLCSA-N 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000000454 talc Substances 0.000 description 5
- 229910052623 talc Inorganic materials 0.000 description 5
- 230000001149 cognitive effect Effects 0.000 description 4
- 239000000902 placebo Substances 0.000 description 4
- 229940068196 placebo Drugs 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000004408 titanium dioxide Substances 0.000 description 3
- ZUSPUYXHFZBBBB-SNVBAGLBSA-N (3r)-3-hydroxy-1-(4-methoxybenzoyl)pyrrolidin-2-one Chemical compound C1=CC(OC)=CC=C1C(=O)N1C(=O)[C@H](O)CC1 ZUSPUYXHFZBBBB-SNVBAGLBSA-N 0.000 description 2
- 208000020401 Depressive disease Diseases 0.000 description 2
- ZXNRTKGTQJPIJK-UHFFFAOYSA-N aniracetam Chemical compound C1=CC(OC)=CC=C1C(=O)N1C(=O)CCC1 ZXNRTKGTQJPIJK-UHFFFAOYSA-N 0.000 description 2
- 229960000793 aniracetam Drugs 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 2
- 230000007787 long-term memory Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000015654 memory Effects 0.000 description 2
- 239000006186 oral dosage form Substances 0.000 description 2
- 239000006201 parenteral dosage form Substances 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 230000006403 short-term memory Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 208000031872 Body Remains Diseases 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 102000010909 Monoamine Oxidase Human genes 0.000 description 1
- 108010062431 Monoamine oxidase Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 230000007278 cognition impairment Effects 0.000 description 1
- 230000003931 cognitive performance Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- YLRFCQOZQXIBAB-RBZZARIASA-N fluoxymesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)C[C@@H]2O YLRFCQOZQXIBAB-RBZZARIASA-N 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 230000010365 information processing Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 1
- 235000015205 orange juice Nutrition 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH29888 | 1988-01-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH26030A true PH26030A (en) | 1992-01-29 |
Family
ID=4183804
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH38119A PH26030A (en) | 1988-01-28 | 1989-01-27 | Use of benzamide in the treatment of cognitive disorders |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US4906626A (ko) |
| EP (1) | EP0326023B1 (ko) |
| JP (1) | JPH07116043B2 (ko) |
| KR (1) | KR960016203B1 (ko) |
| AT (1) | ATE113207T1 (ko) |
| AU (1) | AU620584B2 (ko) |
| CA (1) | CA1332151C (ko) |
| DE (1) | DE58908544D1 (ko) |
| DK (1) | DK171094B1 (ko) |
| ES (1) | ES2063060T3 (ko) |
| HU (1) | HU203042B (ko) |
| IE (1) | IE65409B1 (ko) |
| IL (1) | IL89031A (ko) |
| PH (1) | PH26030A (ko) |
| ZA (1) | ZA89523B (ko) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3751404T2 (de) * | 1986-12-17 | 1995-12-21 | Glaxo Group Ltd | Verwendung von heterocyclischen Verbindungen zur Behandlung von Bewusstseinsstörungen. |
| FR2645742A1 (fr) * | 1989-04-12 | 1990-10-19 | Delagrange Laboratoires | Application de derives de 2-methoxy 4-(4,5-dihydro 2-imidazolyl (ou 2-oxazolyl) amino) 5-chloro benzamide dans le traitement des troubles de la fonction cognitive |
| JP3172202B2 (ja) * | 1990-11-29 | 2001-06-04 | エフ．ホフマン−ラ ロシュ アーゲー | 不安の障害の処置剤 |
| US6951884B2 (en) * | 2002-06-12 | 2005-10-04 | Hoffmann-La Roche Inc. | Fluorobenzamides and uses thereof |
| KR100856141B1 (ko) * | 2003-10-23 | 2008-09-03 | 에프. 호프만-라 로슈 아게 | 모노아민 산화효소 ｂ 저해제로서의 벤즈아제핀 유도체 |
| WO2005053703A1 (en) * | 2003-12-02 | 2005-06-16 | Leslie James Sheldon | Combination therapy for dementia, depression and apathy |
| EP2597087B1 (en) | 2005-10-25 | 2016-03-30 | Shionogi&Co., Ltd. | Dihydrooxazine and tetrahydropyrimidine derivatives as BACE 1 inhibitors |
| US8653067B2 (en) | 2007-04-24 | 2014-02-18 | Shionogi & Co., Ltd. | Pharmaceutical composition for treating Alzheimer's disease |
| CA2683887A1 (en) * | 2007-04-24 | 2008-11-06 | Shionogi & Co., Ltd. | Aminodihydrothiazine derivatives substituted with a cyclic group having inhibitory activity against production of amyloid beta protein |
| AU2009258496B8 (en) * | 2008-06-13 | 2014-06-26 | Shionogi & Co., Ltd. | Sulfur-containing heterocyclic derivative having beta-secretase-inhibiting activity |
| WO2010047372A1 (ja) * | 2008-10-22 | 2010-04-29 | 塩野義製薬株式会社 | Ｂａｃｅ１阻害活性を有する２－アミノピリミジン－４－オンおよび２－アミノピリジン誘導体 |
| BR112012013854A2 (pt) | 2009-12-11 | 2019-09-24 | Shionogi & Co | derivados de oxazina. |
| EP2634186A4 (en) | 2010-10-29 | 2014-03-26 | Shionogi & Co | naphthyridine |
| JP5766198B2 (ja) | 2010-10-29 | 2015-08-19 | 塩野義製薬株式会社 | 縮合アミノジヒドロピリミジン誘導体 |
| WO2012147763A1 (ja) | 2011-04-26 | 2012-11-01 | 塩野義製薬株式会社 | オキサジン誘導体およびそれを含有するｂａｃｅ１阻害剤 |
| JP2016501827A (ja) | 2012-10-24 | 2016-01-21 | 塩野義製薬株式会社 | Ｂａｃｅ１阻害作用を有するジヒドロオキサジンまたはオキサゼピン誘導体 |
| CA3020684A1 (en) | 2016-04-12 | 2017-10-19 | E-Vision Smart Optics, Inc. | Electro-active lenses with raised resistive bridges |
| US10599006B2 (en) | 2016-04-12 | 2020-03-24 | E-Vision Smart Optics, Inc. | Electro-active lenses with raised resistive bridges |
-
1989
- 1989-01-11 CA CA000587927A patent/CA1332151C/en not_active Expired - Lifetime
- 1989-01-13 US US07/297,168 patent/US4906626A/en not_active Expired - Lifetime
- 1989-01-19 ES ES89100901T patent/ES2063060T3/es not_active Expired - Lifetime
- 1989-01-19 AT AT89100901T patent/ATE113207T1/de not_active IP Right Cessation
- 1989-01-19 DE DE58908544T patent/DE58908544D1/de not_active Expired - Lifetime
- 1989-01-19 EP EP89100901A patent/EP0326023B1/de not_active Expired - Lifetime
- 1989-01-23 ZA ZA89523A patent/ZA89523B/xx unknown
- 1989-01-23 IL IL8903189A patent/IL89031A/en unknown
- 1989-01-25 HU HU89303A patent/HU203042B/hu unknown
- 1989-01-25 JP JP1014249A patent/JPH07116043B2/ja not_active Expired - Lifetime
- 1989-01-27 KR KR1019890000867A patent/KR960016203B1/ko not_active IP Right Cessation
- 1989-01-27 PH PH38119A patent/PH26030A/en unknown
- 1989-01-27 AU AU28836/89A patent/AU620584B2/en not_active Expired
- 1989-01-27 IE IE27389A patent/IE65409B1/en not_active IP Right Cessation
- 1989-01-27 DK DK036889A patent/DK171094B1/da not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| AU620584B2 (en) | 1992-02-20 |
| CA1332151C (en) | 1994-09-27 |
| HU203042B (en) | 1991-05-28 |
| KR890011589A (ko) | 1989-08-21 |
| ES2063060T3 (es) | 1995-01-01 |
| AU2883689A (en) | 1989-08-03 |
| IL89031A0 (en) | 1989-08-15 |
| IE890273L (en) | 1989-07-28 |
| JPH01224318A (ja) | 1989-09-07 |
| IL89031A (en) | 1995-07-31 |
| IE65409B1 (en) | 1995-10-18 |
| ZA89523B (en) | 1989-09-27 |
| DK36889D0 (da) | 1989-01-27 |
| HUT50042A (en) | 1989-12-28 |
| US4906626A (en) | 1990-03-06 |
| DE58908544D1 (de) | 1994-12-01 |
| KR960016203B1 (ko) | 1996-12-06 |
| JPH07116043B2 (ja) | 1995-12-13 |
| EP0326023B1 (de) | 1994-10-26 |
| EP0326023A2 (de) | 1989-08-02 |
| EP0326023A3 (en) | 1990-09-05 |
| DK171094B1 (da) | 1996-06-03 |
| ATE113207T1 (de) | 1994-11-15 |
| DK36889A (da) | 1989-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4906626A (en) | Method of use for treatment or prevention of cognitive disorders | |
| RU2334514C1 (ru) | СРЕДСТВО ДЛЯ УЛУЧШЕНИЯ КОГНИТИВНЫХ ФУНКЦИЙ И ПАМЯТИ НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО (4,3-b) ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ | |
| Granacher et al. | Physostigmine: Its use in acute anticholinergic syndrome with antidepressant and antiparkinson drugs | |
| CA1335813C (en) | Administration of monoamine acridines in cholinergic neuronal deficit states | |
| JPS591412A (ja) | 脳血管不全症処置用固形製剤 | |
| TWI549678B (zh) | ４－胺基吡啶於改善具有脫髓鞘及其他神經系統狀況之患者的神經認知及／或神經精神缺陷之用途 | |
| CN104884053B (zh) | 用于改善记忆表现的益智组合物 | |
| US8580301B2 (en) | Psychostimulant containing pharmaceutical composition | |
| DK169656B1 (da) | Anvendelse af adenosinderivater til fremstilling af et lægemiddel med virkning mod demens | |
| CN104582793A (zh) | 用拉喹莫德和氨吡啶的组合治疗多发性硬化症 | |
| CN115776894A (zh) | T型钙通道调节剂的使用方法 | |
| JENSEN et al. | Amnesic effects of diazepam:“Drug dependence” explained by state‐dependent learning | |
| Salako et al. | Artemether in moderately severe and cerebral malaria in Nigerian children | |
| Morrison et al. | Further studies on the relation between in vitro disintegration time of tablets and the urinary excretion rates of riboflavin | |
| JP2023534930A (ja) | 医薬組成物およびその適用 | |
| CN115867272A (zh) | 肠道选择性jak3抑制剂的给药 | |
| Skelly et al. | Biopharmaceutic considerations in designing and evaluating novel drug delivery systems | |
| Wiest et al. | Stability of flecainide acetate in an extemporaneously compounded oral suspension | |
| Toma et al. | Incidence of Yersinia enterocolitica and Y. pseudotuberculosis infections in Canada; 1975 semiannual report. | |
| US5075312A (en) | Novel anti-micturition composition and method | |
| Mercer et al. | Lack of an effect of zolmitriptan (Zomig, 311C90) on psychometric task performance: results of a placebo-controlled study in healthy volunteers | |
| US5075314A (en) | Antimicturition composition and novel method | |
| CA2334611A1 (en) | Use of a nk-1 receptor antagonist for treating psychiatric disorders | |
| Uchida et al. | Pharmacokinetics of YM905, a novel, bladder-selective antimuscarinic, are not adversely affected by food | |
| CERANAPRIL | 213 COMBINED THYROTROPIN-RELEASING HORMONE (TRH)-PHYSOSTIGMINE INFUSIONS IN ALZHEIMER'S DISEASE (AD): INITIAL RESULTS WITH A PEPTIDE-ENHANCEMENT STRATEGY Alan M. Mellow, Stephen M. Aronson, Bruno Giordani |